11 December 2013
Clifford Chance advises Amdipharm Mercury (AMCo) on its acquisition of Abcur
International law firm Clifford Chance advised Amdipharm Mercury (AMCo) on its acquisition of Sweden-based Abcur AB.
Abcur is a specialty pharmaceutical business with a focus on the development, registration and marketing of a wide range of specialised prescription and non-prescription products within the Nordic markets for a number of therapeutic indications including addiction, intensive care, pain management and anaesthesia.
Earlier this year, Clifford Chance advised AMCo on its acquisition of the Fucithalmic® pharmaceutical product business of Danish LEO Pharma A/S.
AMCo is an international specialty pharmaceuticals group formed from the merger of Amdipharm and Mercury Pharma. Clifford Chance acted for private equity firm Cinven when it acquired Amdipharm and Mercury Pharma in 2012. The deals were significantly complex as they had to be conducted in parallel rather than sequentially and represented one of the largest UK buyouts that year. This mandate won Clifford Chance 'Corporate Finance Team of the Year' at The Lawyer Awards 2013.
The Clifford Chance team for the Abcur acquisition was led by Corporate partner Andre Duminy and senior associates Christopher Sullivan and Toby Parkinson. Roschier advised on Swedish law aspects and Deloitte provided financial and tax advice.